Individualized Immune Prognostic Signature in Early-Stage Nonsquamous NSCLC

This multiple-cohort study assesses a robust, individualized immune signature for estimating prognosis in patients with early-stage nonsquamous non–small cell lung cancer.

http://ift.tt/2tkYyy0